Serine palmitoyltransferase 2

BE0000660ProteinHumansSPTLC2

Component of the serine palmitoyltransferase multisubunit enzyme (SPT) that catalyzes the initial and rate-limiting step in sphingolipid biosynthesis by condensing L-serine and activated acyl-CoA (most commonly palmitoyl-CoA) to form long-chain bases (PubMed:19416851, PubMed:19648650, PubMed:20504773, PubMed:20920666). It is acted on by 2 drugs in DrugBank.

Gene name
SPTLC2
UniProtKB entry
O15270Swiss-Prot
Cellular location
Endoplasmic reticulum membrane
Residues / weight
562 residues · 62,924 Da
Also known as
2.3.1.50 · KIAA0526 · LCB 2 · LCB2 · LCB2a

Resolves to

Protein
UniProtO15270UniProt nameSPTC2_HUMAN
Gene
HGNCHGNC:11278NCBI Gene9517GenBank2564249GeneCardsSPTLC2
Pharmacology
KEGGhsa:9517
Structure
PDB6M4NPDB6M4OPDB7CQI
Drugs

What you can answer from here — as of September 07, 2019

2DrugsApproved to experimental, with action, bond type and pharmacological action
Sign in
7GO termsFunction, process and component, as structured annotations
Sign in
1Pfam domainDomain architecture mapped to Pfam families and clans
Sign in
17+ReferencesStructured and connected to the statements they support
Sign in

Which approved drugs act on Serine palmitoyltransferase 2, how selective are they, and which programs against it are still in active trials?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In